<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03800563</url>
  </required_header>
  <id_info>
    <org_study_id>ALM-Lipo-002</org_study_id>
    <nct_id>NCT03800563</nct_id>
  </id_info>
  <brief_title>Laser Assisted Liposuction and Facial Autologous Fat Grafting With the LipoLife System</brief_title>
  <official_title>The Safety and Efficacy of Laser Assisted Liposuction and Facial Autologous Fat Grafting With the LipoLife System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alma Lasers</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alma Lasers</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, prospective, open-label, single arm study. The study aims to evaluate the
      safety and efficacy of Laser Assisted Liposuction procedure performed with the LipoLife
      system. The study will include twenty (20) eligible subjects, that are willing to undergo
      abdominal or outer thighs laser-assisted liposuction. Five to twenty (5-20) subjects out of
      this study group should also be eligible for facial fat grafting. Follow up visits to
      evaluate study endpoints will take place at 1, 3 and 6 months after the surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2018</start_date>
  <completion_date type="Anticipated">March 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blinded comparison of before and after photographs</measure>
    <time_frame>3 months</time_frame>
    <description>Improvement in aesthetic appearance as determined by blinded comparison of before and after photographs.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Laser Assisted Liposuction</condition>
  <arm_group>
    <arm_group_label>Laser assisted liposuction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laser Assisted Liposuction with the LipoLife system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LipoLife system</intervention_name>
    <description>Abdominal/ Outer thighs Laser Assisted Liposuction. Five to twenty subjects out of the study group will also undergo facial fat grafting.</description>
    <arm_group_label>Laser assisted liposuction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with excessive fat in the lower abdomen or subjects with excessive fat in the
             outer thighs that are willing to undergo laser-assisted liposuction

          -  Estimated fat harvesting of 1-3 liters

          -  Subjects (5-20) eligible for facial fat grafting of at least 5 cc for each cheek

          -  Between 18 and 70 years of age

          -  Provided written Informed Consent

        Exclusion Criteria:

          -  Body Mass Index (BMI) &gt;35

          -  Sever skin laxity

          -  Positive pregnancy test

          -  Current smoker

          -  Presence of known malignancy

          -  Active infection in the treatment area

          -  History of autoimmune disorder (e.g., Systemic Lupus Erythematosus [SLE])

          -  History of connective, metabolic or atrophic skin disease

          -  History of keloid scarring

          -  Chronic use (&gt;7 consecutive days) of anticoagulants (such as aspirin) or NSAIDs within
             15 days prior to enrollment

          -  Subjects with immune system diseases

          -  Subject unable to follow post-treatment instructions

          -  Any other reason that in the opinion of the investigator, prevents the subject from
             participating in the study or compromise the subject safety.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason N. Pozner, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sanctuary Plastic Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lior Heller, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yitzhak Shamir Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason N. Pozner, M.D.</last_name>
    <phone>561-367-9101</phone>
    <email>drpozner@spsboca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sanctuary Plastic Surgery</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Pozner, M.D.</last_name>
      <phone>561-367-9101</phone>
      <email>drpozner@spsboca.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yitzhak Shamir Medical Center</name>
      <address>
        <city>Be'er Ya'aqov</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lior Heller, M.D.</last_name>
      <phone>+972-8-9778354</phone>
      <email>plastic@asaf.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>January 9, 2019</study_first_submitted>
  <study_first_submitted_qc>January 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2019</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

